Geron (GERN) Cash from Financing Activities (2010 - 2026)
Geron (GERN) posted Cash from Financing Activities of $2.4 million for Q1 2026, up 541.53% sequentially from $378000.0 in Q4 2025, and up 847.27% YoY from $256000.0 in Q1 2025.
Geron (GERN) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Geron has reported Cash from Financing Activities for 17 years, with the latest figure at $2.4 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 847.27% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (down 97.63% YoY) and the FY2025 annual result came in at $2.3 million, down 99.32% from the prior year.
- Cash from Financing Activities rose to $2.4 million in Q1 2026 per GERN's latest filing, from $378000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $281.0 million in Q1 2023 and troughed at $256000.0 in Q1 2025.
- A 5-year average of $47.9 million and a median of $11.9 million in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities sank 99.83% in 2025, then jumped 847.27% in 2026.
- Over 5 years, Cash from Financing Activities stood at $11.9 million in 2022, then soared by 179.12% to $33.3 million in 2023, then surged by 399.29% to $166.2 million in 2024, then tumbled by 99.77% to $378000.0 in 2025, then jumped by 541.53% to $2.4 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $2.4 million, $378000.0, and $542000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | 1.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.38 Mn |
| Jun 30, 2026 | 1.38 Mn |
| Mar 31, 2026 | 2.43 Mn |
| Mar 31, 2026 | 2.43 Mn |
| Dec 31, 2025 | 378,000.00 |
| Dec 31, 2025 | 378,000.00 |
| Sep 30, 2025 | 542,000.00 |
| Sep 30, 2025 | 542,000.00 |
| Jun 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 1.09 Mn |
| Mar 31, 2025 | 256,000.00 |
| Mar 31, 2025 | 256,000.00 |
| Dec 31, 2024 | 166.16 Mn |
| Dec 31, 2024 | 166.16 Mn |
| Sep 30, 2024 | 3.58 Mn |
| Sep 30, 2024 | 3.58 Mn |
| Jun 30, 2024 | 16.83 Mn |
| Jun 30, 2024 | 16.83 Mn |
| Mar 31, 2024 | 147.80 Mn |
| Mar 31, 2024 | 147.80 Mn |